N-[1-[3-(1-aminocyclobutyl)-1,2,4-oxadiazol-5-yl]-2-methylpropyl]-2-chloro-4-(trifluoromethyl)aniline;hydrochloride
C17H21Cl2F3N4O — CID 120859373
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[1-[3-(1-aminocyclobutyl)-1,2,4-oxadiazol-5-yl]-2-methylpropyl]-2-chloro-4-(trifluoromethyl)aniline;hydrochloride
N-[1-[3-(1-aminocyclobutyl)-1,2,4-oxadiazol-5-yl]-2-methylpropyl]-2-chloro-4-(trifluoromethyl)aniline;hydrochloride (PubChem CID 120859373) has the molecular formula C17H21Cl2F3N4O and a molecular weight of 425.28 g/mol. Its IUPAC name is N-[1-[3-(1-aminocyclobutyl)-1,2,4-oxadiazol-5-yl]-2-methylpropyl]-2-chloro-4-(trifluoromethyl)aniline;hydrochloride.
Molecular Properties
| Compound Name | N-[1-[3-(1-aminocyclobutyl)-1,2,4-oxadiazol-5-yl]-2-methylpropyl]-2-chloro-4-(trifluoromethyl)aniline;hydrochloride |
|---|---|
| PubChem CID | 120859373 |
| Molecular Formula | C17H21Cl2F3N4O |
| Molecular Weight | 425.28 g/mol |
| Exact Mass | 424.10 |
| IUPAC Name | N-[1-[3-(1-aminocyclobutyl)-1,2,4-oxadiazol-5-yl]-2-methylpropyl]-2-chloro-4-(trifluoromethyl)aniline;hydrochloride |
| SMILES | CC(C)C(Nc1ccc(C(F)(F)F)cc1Cl)c1nc(C2(N)CCC2)no1.Cl |
| InChI | InChI=1S/C17H20ClF3N4O.ClH/c1-9(2)13(14-24-15(25-26-14)16(22)6-3-7-16)23-12-5-4-10(8-11(12)18)17(19,20)21;/h4-5,8-9,13,23H,3,6-7,22H2,1-2H3;1H |
| InChIKey | AFYMTFKALTZONB-UHFFFAOYSA-N |
| XLogP | 5.31 |
| TPSA | 76.97 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 27 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 425.28 |
| LogP ≤ 5 | 5.31 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 120859373 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.